David T. Rubin, MD is a professor of medicine at the University of Chicago, director of the Inflammatory Bowel Disease Center, and chair of the International Organization for the Study of IBD (IOIBD).

Most patients with moderately to severely active 

 who reached histologic remission on guselkumab maintained it through 3 years, according to a post hoc analysis of the QUASAR long-term extension (LTE). The findings were presented at the 

American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Among patients in histologic remission at the start of maintenance, 75.9% receiving guselkumab 100 mg every 8 weeks and 81.3% receiving 200 mg every 4 weeks remained in histologic remission at maintenance week 140.

Although histologic outcomes are frequently reported in UC trials, long-term changes over multiple years have not been well characterized.

David Rubin, MD, of the University of Chicago Medicine Inflammatory Bowel Disease Center, told 

 the analysis shows histologic remission is achievable in most responders and relatively stable once reached.

Guselkumab in Ulcerative Colitis: Is Histologic Remission Durable?

QUASAR Long-Term Extension Design and Histologic Assessment

QUASAR enrolled adults with a modified Mayo score of 5 to 9, a rectal bleeding subscore ≥ 1, and an endoscopic subscore of 2 or 3.

 Patients in clinical response 12 weeks after intravenous guselkumab induction were randomly assigned in a 1:1:1 ratio to subcutaneous guselkumab 100 mg every 8 weeks, 200 mg every 4 weeks, or placebo. In the primary maintenance analysis, clinical remission at week 44 was achieved by 45% and 50% of patients receiving guselkumab, respectively, vs 19% with placebo.

Patients receiving 100 mg who lost response between maintenance weeks 8 and 32 received a blinded dose adjustment to 200 mg every 4 weeks. Biopsies were collected at induction baseline and at maintenance weeks 0, 44, 92, and 140, and scored using the Geboes system. The analysis included 137 patients in the 100-mg group and 130 in the 200-mg group with evaluations at every time point.

Histologic remission was defined as the absence of neutrophils in the lamina propria and epithelium, with no crypt destruction, erosions, ulcerations, or granulation tissue. In the LTE randomized population, 38.7% and 41.9% of patients had a prior inadequate response or intolerance to advanced therapy.

Histologic Improvement Through 3 Years of Guselkumab

At induction baseline, 91.9% of patients in the 100-mg group and 86.1% in the 200-mg group had Geboes scores of 3.2 to 5.4. After 12 weeks of intravenous induction, 62.7% and 63.9%, respectively, had Geboes scores of 0.0 to 3.1. This proportion rose to 76.6% and 83.9% at maintenance week 44 and held at 79.6% and 83.1% at week 140.

The proportion of patients with the most severe Geboes scores of 5.3 or 5.4 fell from 28.4% and 26.1% at induction baseline to 5.8% and 6.9% at maintenance week 0, reaching 3.6% and 2.3% at week 140.

At the start of maintenance, 56.4% (79/140) of patients receiving 100 mg and 57.3% (75/131) receiving 200 mg were in histologic remission. Of these, 75.9% (60/79) and 81.3% (61/75) remained in remission at week 140, and 53.2% (42/79) and 61.3% (46/75) were in remission at every maintenance time point.

“If you had histological remission at the end of 1 year, you were likely to still be there at the ends of 2 and 3 years,” Rubin explained.

He noted most gains occurred within the first year of treatment, with little additional improvement afterward. He added the 200-mg dose appeared numerically more effective, although the analysis was not powered to compare doses.

Histology, Endoscopy, and Treatment Targets in UC

The investigators reported histologic improvement trends over time were similar to previously reported endoscopic trends in QUASAR.

 Rubin said Mayo endoscopic scores appeared less healed than histology at corresponding time points, and he outlined possible explanations, including histologic improvement preceding visible mucosal healing.

“My own hypothesis is that it starts with histological improvement,” said Rubin. “That’s where the therapy might be working directly and having an effect, and the mucosa catches up later, and that might be why we’re seeing what we see.”

Rubin said the next step is determining whether treatment decisions should be guided by symptoms, endoscopy, histology, or all 3. He pointed to the VERDICT trial of vedolizumab, being presented at United European Gastroenterology Week, as a complementary study testing whether targeting histologic remission improves outcomes.

Editors’ note: Rubin reports relevant disclosures with AbbVie, Abivax, Bristol Myers Squibb, Celltrion, Eli Lilly, Genentech, J&J, and others.

Rubin DT, Allegretti JR, Alvarez Y, et al. Histology outcomes over time in patients with moderately to severely active ulcerative colitis treated with guselkumab in the QUASAR long-term extension study. Presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN.

Rubin DT, Allegretti JR, Panés J, et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025;405(10472):33-49. doi:10.1016/S0140-6736(24)01927-5

Videos

David Rubin, MD, discusses QUASAR extension data showing most patients in histologic remission on guselkumab stayed there through 3 years of maintenance.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Credit: Children's Hospital of Philadelphia

 in infants and toddlers presenting to a pediatric emergency department was predominantly food-triggered and tended to resolve after a single intramuscular epinephrine dose, according to a new retrospective cohort study published in 

Colleen M. Shannon, MD, MPH, from Children's Hospital of Philadelphia, and colleagues designed the study to characterize the clinical presentation and emergency management of anaphylaxis in patients aged 0 to 24 months.¹ Cases were confirmed using the 2006 National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) clinical criteria, which apply across age groups without infant-specific modifications.² The analysis captured presenting symptoms, administered treatments, and disposition for each confirmed case.¹

Infant Anaphylaxis Symptoms and Food Triggers in the Emergency Department

The investigators retrospectively screened encounters at a pediatric emergency department between June 2019 and June 2022 using anaphylaxis-associated International Classification of Diseases, Ninth and 10th Revision codes.¹ Using electronic medical records, the team reviewed each patient’s presenting symptoms, the treatments they received, and whether they were discharged or admitted.

Of 225 potentially eligible encounters identified by diagnostic code, 155 patients met inclusion criteria on chart review.¹ The median age was 10.8 months (interquartile range [IQR], 8.4 to 15.6), and food triggered 96.1% (149/155) of episodes.¹

Skin and mucosal symptoms were the most common presentation, occurring in 99.4% of patients.¹ Gastrointestinal symptoms were documented in 74.2% and respiratory symptoms in 57.4%.¹ Cardiovascular symptoms occurred in 5.8% of patients.¹

Epinephrine Dosing and Disposition in Infants and Toddlers with Anaphylaxis

Intramuscular epinephrine was administered to 87.1% of patients, and 90.4% of those treated received a single dose.¹ The remaining 12.9% of patients did not receive epinephrine in the emergency department.¹ The investigators also tracked use of antihistamines, corticosteroids, albuterol, and intravenous fluids as treatments of interest.¹

Most patients, 88.4%, were discharged home from the emergency department. None of the admitted patients required additional epinephrine after admission.¹

In their conclusions, the investigators described the typical reaction in this age group as food-triggered and mucocutaneous, with gastrointestinal and/or mild-to-moderate respiratory involvement.¹ Severe respiratory or cardiovascular involvement was uncommon.¹ Symptoms tended to resolve after 1 epinephrine dose, and most patients did not require hospitalization.¹

The findings provide emergency and allergy clinicians with age-specific data on symptom distribution, epinephrine response, and disposition for patients younger than 2 years presenting with suspected anaphylaxis.¹ Mild-to-moderate respiratory involvement and gastrointestinal symptoms accompanied mucocutaneous findings in most reactions, a pattern clinicians can weigh when applying NIAID/FAAN criteria to patients unable to report subjective symptoms.¹,²

Because the cohort included only reactions prompting emergency department evaluation, the findings describe the presentations clinicians are most likely to encounter in acute care settings rather than the full spectrum of infant reactions managed at home.¹ The investigators also noted that the data was analyzed descriptively.

Recognizing Anaphylaxis in Nonverbal Infants and Toddlers

The findings build on recent HCPLive coverage of anaphylaxis recognition in young children. In an August 2026 Q&A, Jay Lieberman, MD, professor at the University of Tennessee Health Science Center, discussed atypical presentations in infants and toddlers and persistent epinephrine underuse.³

Lieberman pointed to fussiness, inconsolable crying, putting a finger in the mouth, and ear tugging as possible signs of oral, throat, or ear canal itching in patients unable to describe their symptoms.³ He also noted clinicians may dismiss vomiting as a minor illness. This point is relevant here, since 74.2% of patients in the 

 cohort presented with gastrointestinal involvement.¹,³

“Infants shouldn’t be treated any differently,” Lieberman said. “If we think they’re having anaphylaxis, they should get epinephrine.”

Shannon CM, Trofa M, Lavelle J, et al. Anaphylaxis in infants and toddlers presenting to a pediatric emergency department. 

Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report. 

Lieberman J. Q&A: Anaphylaxis Recognition and Epinephrine Use, With Jay Lieberman, MD. HCPLive. Published August 14, 2026. Accessed October 13, 2026. 

https://www.hcplive.com/view/anaphylaxis-recognition-epinephrine-use-jay-lieberman-md

Articles

Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Infant Anaphylaxis Often Resolves After a Single Epinephrine Dose

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Crohn disease (CD) or ulcerative colitis (UC)

 who restarted infliximab as subcutaneous (SC) infliximab 240 mg after an interruption in intravenous (IV) therapy had detectable anti-drug antibodies (ADAs). Even so, clinical outcomes were generally similar regardless of prior ADA status, according to a post hoc analysis of the phase 3 LIBERTY-CD and LIBERTY-UC trials presented at the 

ADAs can compromise IV infliximab reinitiation after a drug holiday, and therapeutic drug monitoring is recommended before restarting IV therapy. Data on SC infliximab initiation after a drug holiday are limited, particularly regarding prior ADA status, according to investigators led by Marla Dubinsky, MD, of the Icahn School of Medicine at Mount Sinai.

 The SC formulation, infliximab-dyyb (Zymfentra), received US Food and Drug Administration approval in October 2023 for maintenance treatment of UC and CD following IV induction.

Which Patients Restarted Infliximab After a Drug Holiday in LIBERTY?

In LIBERTY, patients received open-label IV infliximab 5 mg/kg at weeks 0, 2, and 6, and week 10 responders were randomized to SC infliximab 120 mg or placebo every 2 weeks. From week 22 through week 102, patients could escalate to SC infliximab 240 mg every 2 weeks for loss of response or at physician discretion.

This analysis focused on 51 patients with CD and 77 with UC in the placebo arm who later initiated SC infliximab 240 mg. Prior ADA positivity was defined as ADA detection at least once between week 10 and SC initiation, using a drug-tolerant electrochemiluminescence assay.

Overall, 72.5% (37/51) of patients with CD and 92.2% (71/77) with UC were ADA positive before SC initiation. The median interval from the last IV infusion to SC initiation was 16 weeks in all subgroups.

ADA-positive patients were less likely to be receiving immunomodulators than ADA-negative patients (CD, 16.2% vs 50.0%; UC, 18.3% vs 50.0%). Among patients with CD, ADA-positive patients also had higher median baseline Crohn’s Disease Activity Index scores (318.1 vs 273.1) and C-reactive protein (CRP) levels (10.4 vs 3.6 mg/L).

Did Prior ADAs Affect Response to SC Infliximab 240 mg?

Clinical response emerged by 8 ± 2 weeks after SC initiation and was sustained through 78 to 80 weeks in both diseases. In CD, clinical remission and response rates at the final assessment were 86.7% (13/15) and 93.3% (14/15) among ADA-positive patients vs 81.8% (9/11) and 90.9% (10/11) among ADA-negative patients.

In UC, partial clinical remission and response rates were 69.2% (18/26) and 96.2% (25/26) among ADA-positive patients vs 100% (3/3) for both end points among ADA-negative patients. Clinical remission and response by modified Mayo score were 62.1% (18/29) and 79.3% (23/29) vs 66.7% (2/3) and 100% (3/3), respectively.

Median CRP levels fell by the first assessment at 8 ± 2 weeks, and median fecal calprotectin levels fell by the first measurement at 32 ± 2 weeks. Both reductions were maintained through 78 to 80 weeks regardless of prior ADA status.

What Happened to Infliximab Levels and ADAs on SC Therapy?

Serum infliximab concentrations rose substantially after SC infliximab 240 mg initiation in both ADA subgroups and converged over time.¹ Among patients with pre-existing ADAs, ADA positivity declined during SC treatment, reaching 66.7% in CD and 65.5% in UC at the last assessment, 78 to 80 weeks after initiation. De novo ADA development was uncommon among patients without prior ADAs.

The investigators concluded pre-existing ADAs did not appear to compromise outcomes after SC infliximab initiation following a drug holiday, and noted the decline in ADA positivity warrants further mechanistic study.

Dubinsky MC, Sands BE, Abraham BP, et al. Impact of prior anti-drug antibody status on clinical outcomes following subcutaneous infliximab initiation after intravenous infliximab interruption: a post hoc analysis of LIBERTY-CD and -UC studies. Presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN.

Hanauer SB, Sands BE, Schreiber S, et al. Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY). Gastroenterology. 2024;167(5):919-933. doi:10.1053/j.gastro.2024.05.006

Campbell P. FDA approves first subcutaneous infliximab for maintenance therapy in UC and Crohn disease. HCPLive. Accessed October 13, 2026. 

https://www.hcplive.com/view/fda-approves-first-subcutaneous-infliximab-for-maintenance-therapy-in-uc-and-crohn-disease

In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

Maria Abreu, MD, is Executive Director of the F. Widjaja Inflammatory Bowel Disease Institute at Cedars-Sinai.

Once-daily oral icotrokinra maintained clinical efficacy with no new safety signals for approximately 1.5 years in adults with moderately to severely active 

, according to data from the ANTHEM-UC long-term extension (LTE) presented at the 

Results showed most of the 136 icotrokinra-treated participants entering the extension achieved clinical response, clinical remission, and endoscopic improvement at week 76, and 87% remained on treatment through week 78.

Icotrokinra is a first-in-class targeted oral peptide which binds the interleukin (IL)-23 receptor, blocking IL-23 signaling at the receptor rather than at the cytokine.

 It received US Food and Drug Administration approval as Icotyde in March 2026 for moderate to severe plaque psoriasis.

 Maria Abreu, MD, Cedars Sinai, presented the LTE results at ACG.

Oral Icotrokinra for Ulcerative Colitis: 76-Week ANTHEM-UC Data

How Was the ANTHEM-UC Long-Term Extension Designed?

In the phase 2b, randomized, double-blind ANTHEM-UC trial, adults with a modified Mayo score of 5 to 9 and a Mayo endoscopic subscore ≥ 2 received icotrokinra 100 mg, 200 mg, or 400 mg once daily or placebo (1:1:1:1). Randomization was stratified by prior inadequate response or intolerance to advanced therapy and by Mayo endoscopic subscore. All 3 doses met the week 12 primary end point of clinical response, with durable efficacy through week 28.

Participants with an inadequate response at week 16 underwent a blinded treatment adjustment, with placebo recipients switched to icotrokinra 400 mg and icotrokinra recipients receiving a sham adjustment. Those in clinical response at week 28 could continue study treatment in the LTE, where adjustments to 5-aminosalicylates, corticosteroids, and immunomodulators were permitted. Placebo recipients were discontinued after unblinding.

Clinical response, clinical remission, and endoscopic improvement were evaluated at week 76, and symptomatic remission was assessed at each visit. Nonresponder imputation was applied without statistical testing, and the final safety visit occurred at week 78.

How Durable Was Icotrokinra Efficacy Through Week 76?

Among the 136 LTE participants, the majority achieved clinical response, clinical remission, and endoscopic improvement at week 76. Of participants in clinical remission at week 76, 97% were also corticosteroid free. Symptomatic remission, observed as early as week 4, was maintained or improved through week 76.

Abreu pointed to the 87% treatment retention rate as a key finding of the extension.

“In reality, people vote with their feet, right?” said Abreu in an interview with 

. “If they’re not doing well, they’re going to move on and go on to something else.”

Abreu noted the 400-mg group enrolled participants with more extensive disease and greater prior exposure to multiple therapies, an imbalance arising by chance in the phase 2 study.

What Did Long-Term Safety Data Show for Icotrokinra in UC?

Icotrokinra was well tolerated, and no new safety signals were identified. Through week 78 in the full analysis set, exposure-adjusted rates of adverse events (AEs), serious AEs, AEs leading to discontinuation, and infections per 100 patient-years were similar to or lower than placebo. No deaths occurred, and one AE of interest, ductal carcinoma in situ, was reported in the 100-mg group during the LTE.

Abreu said she expects the oral IL-23 receptor blocker to be used early in the UC treatment course, after mesalamine or corticosteroids, drawing on clinicians’ experience with injectable IL-23 inhibitors.

“Before they get to a subQ or an IV infusion, I think this is going to be very, very legit,” said Abreu. “It’s very effective. It’s very safe.”

Editors’ Note: Relevant disclosures for Abreu include AbbVie, Alimentiv, Bristol Myers Squibb, Genentech, Johnson & Johnson, Lilly, Pfizer, and others.

Abreu MT, et al. Long-term efficacy and safety of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in ulcerative colitis: results from the ANTHEM-UC long-term extension. Presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN.

Johnson & Johnson. Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients. Accessed October 13, 2026. 

https://www.jnj.com/media-center/press-releases/icotrokinra-meets-primary-endpoint-of-clinical-response-in-ulcerative-colitis-study-and-shows-potential-to-transform-the-treatment-paradigm-for-patients

Campbell P. Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis. HCPLive. Published March 18, 2026. Accessed October 13, 2026. 

https://www.hcplive.com/view/icotrokinra-receives-fda-approval-for-psoriasis

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC. 

Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE

Yasir Qazi, MD, is a transplant nephrologist at Providence St. Joseph Hospital in Orange, California, associate professor of clinical medicine at the Keck School of Medicine of USC.

Isolated microvascular inflammation (MVI) can signal injury in a transplanted kidney even when creatinine levels remain stable and donor-specific antibodies are undetectable. Despite its association with poorer graft outcomes, no treatments are currently approved specifically for this condition.

, Yasir Qazi, MD, a transplant nephrologist at Providence St. Joseph Hospital in Orange, California, associate professor of clinical medicine at the Keck School of Medicine of USC, and an investigator on the phase 2 TRANSPIRE trial of felzartamab, explained why this inflammation can go unrecognized until more substantial kidney injury has occurred.

Felzartamab and the Hidden Injury of Isolated MVI, With Yasir Qazi, MD

“Creatinine, which is a reflection of how well the kidney is functioning, is a sum total of at least 1 million nephrons in the kidney, and if only 10, 15, 20, 30 nephrons are getting implicated with, let’s say, microvascular inflammation, the rest of the nephrons are doing a great job in fooling us to think that nothing’s going on in the kidney,” Qazi said.

One way this otherwise hidden injury has come into focus is through biomarkers. Qazi described how transplant centers began identifying patients with stable kidney function but abnormal biomarker findings, prompting biopsies that revealed MVI. Because a transplanted kidney carries DNA distinct from its recipient, donor-derived cell-free DNA can provide a signal of graft injury even before conventional measures of kidney function change.

The 2022 Banff classification recognized DSA-negative, C4d-negative MVI as a distinct phenotype,² and subsequent research associated this finding with approximately twice the risk of graft failure compared with patients without rejection.³ Together, these developments have drawn attention to inflammatory processes that may have previously gone undetected.

Qazi suggested that such injury could help explain why achieving decades of graft survival remains challenging, even as transplant medicine has advanced. He also noted that the Banff classification was undergoing further updates at the time of the interview, potentially refining how these inflammatory findings are characterized.

Testing Anti-CD38 Felzartamab in Isolated MVI

The Biogen-sponsored phase 2 TRANSPIRE trial is investigating whether felzartamab can resolve isolated MVI in kidney transplant recipients.¹ The investigational anti-CD38 monoclonal antibody targets CD38-expressing cells, including natural killer (NK) cells and plasma cells, which may contribute to inflammatory pathways involved in graft injury.

Qazi explained that targeting these cell populations could potentially interrupt a cycle in which inflammation activates additional damaging pathways, a process he described as “injury begets more injury.”

Adults with late isolated MVI are randomized to felzartamab or placebo for 24 weeks, followed by open-label felzartamab through week 52. The primary endpoint is biopsy-proven resolution of MVI, with results expected in 2028.

The study builds on felzartamab research in antibody-mediated rejection, including the phase 3 TRANSCEND trial, but extends investigation to patients whose MVI occurs without detectable donor-specific antibodies.

For Qazi, the significance of intervening at this stage extends beyond whether inflammation resolves on biopsy. The larger question is whether addressing injury before creatinine rises or protein appears in the urine could change the subsequent course of graft deterioration.

“We hope that this is going to protect that kidney from even having to go through a phase where you spill protein or you have a rise in the creatinine,” Qazi said.

Whether histologic resolution translates into longer graft survival remains to be established. Still, Qazi views earlier recognition and treatment of microvascular injury as a potential step toward a longstanding goal in transplant nephrology: one kidney for life.

Editors’ Note: Disclosures for Qazi include Natera, CareDx, and Eurofins. TRANSPIRE is sponsored by Biogen.

1. ClinicalTrials.gov. TRANSPIRE. ClinicalTrials.gov identifier: NCT07219043. 

https://clinicaltrials.gov/study/NCT07219043

2. Naesens M, Roufosse C, Haas M, et al. The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant. 2024;24(3):338-349. doi:

3. Sablik M, Sannier A, Raynaud M, et al. Microvascular inflammation of kidney allografts and clinical outcomes. N Engl J Med. 2025;392(8):763-776. doi:

TRANSPIRE investigator Yasir Qazi, MD, explains how isolated MVI can signal kidney transplant injury before creatinine rises.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Raj Vuppalanchi, MD, is a Professor of Medicine, Director of Hepatology, and Associate Program Director at the Indiana University School of Medicine.

In an EPICS-III subgroup analysis, Raj Vuppalanchi, MD, explains why saroglitazar’s larger US treatment effect may reflect differences in disease biology.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Regional Differences in Saroglitazar Response in PBC, With Raj Vuppalanchi, MD

Shawn Kwatra, MD, discusses ADtouch data showing lebrikizumab improved clearance, itch, pain, and satisfaction in hand and foot atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

ADtouch: Lebrikizumab Eases Itch and Pain in Hand and Foot Eczema

David Rosmarin, MD, discusses 52-week phase 2b REZOLVE-AA data on rezpegaldesleukin in severe alopecia areata presented at EADV 2026.

Alopecia

Rezpegaldesleukin Hair Regrowth Climbs Through 1 Year in AA: David Rosmarin, MD

Ayah Matar, MD, is a postdoctoral researcher at Mayo Clinic.

Ayah Matar, MD, discusses findings showing elevated serum 7αC4 in SIBO-positive patients, suggesting overlap between SIBO and bile acid diarrhea.

SIBO Tied to Higher Bile Acid Synthesis in Patients With Chronic Diarrhea

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.

FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help? 

Clinicians at CHEST 2026 will see late-breaking COPD, asthma, pulmonary hypertension, and bronchoscopy data, plus exclusive expert interviews.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

CHEST 2026 Preview: Late-Breakers to Watch Out For

Professor and the Founding Chair for the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra / Northwell

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD

Takashi Miki, MD, PhD, is the dean of the Graduate School of Medicine at Chiba University

A Cell Reports mouse study found hepatic steatosis fell without weight loss through separate iNKT cell and GLP-1 pathways.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Bile Acid HDCA Reduces Liver Fat via PPARα, With Takashi Miki, MD, PhD

Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Latest News

Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years

Infant Anaphylaxis Often Resolves After a Single Epinephrine Dose

LIBERTY: Prior Anti-Drug Antibodies Did Not Blunt SC Infliximab After Drug Holiday

Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE

Felzartamab and the Hidden Injury of Isolated MVI, With Yasir Qazi, MD